2010 (v1)
Publication
To evaluate the cardiotoxicity, general toxicity, and activity of non-pegylatecl liposomal doxorubicin, in combination with docetaxel and trastuzumab, as first-line therapy in metastatic breast cancer.Thirty-one patients with metastatic human epidermal growth factor receptor 2-overexpressing breast cancer, who had not previously received...
Uploaded on: February 4, 2024